Elast Technologies Receives Speculative Buy Recommendation From Donner Corp. International.

Business Editors/Health & Medical Writers

LAS VEGAS--(BUSINESS WIRE)--June 27, 2000

ELAST Technologies, Inc., (OTC-BB: ESTG) www.elast.com announced that Donner Corp. International will initiate coverage on ELAST Technologies as a speculative buy recommendation in the medical/pharmaceutical diagnostic equipment industry.

Donner Corp., an investment-banking firm and member of NASD and SIPC, headquartered in Santa Ana, California, issued a thorough research report yesterday analyzing the investment opportunity offered by ELAST Technologies and concluding that, as ELAST has the potential for substantial growth, its stock is "highly undervalued".

Donner Corp. cited three factors in support of its recommendation. Most notable is the potential of ELAST's patented allergy testing device to "revolutionize (the) multi-billion dollar (allergy testing) industry ... as more than 300 million people in the U.S. and Europe have allergy/sensitivity problems." Donner also considered ELAST Technologies' possible merger with the Maryland based Bioelectronics Corporation and the concomitant expansion of ELAST's market focus. The primary product of Bioelectronics Corporation is the Portic Electronic Bandage, an inexpensive and disposable adjunctive wound healing treatment that accelerates the healing of soft and hard tissue wounds. In further support of its conclusion that ELAST's stock is "highly undervalued" Donner Corp. noted ELAST Technologies' "highly experienced and renowned team of management professionals."

View the complete report at www.elast.com.

ELAST Technologies is a research and development enterprise whose primary business is the development of the Electronic Allergo Sensitivity Test (ELAST Device(TM)). The ELAST Device(TM) is a patented, non-invasive diagnostic tool designed to accurately diagnose allergies, as well as food and chemical sensitivities immediately and without any of the pain or expense associated with currently employed testing methods. The technology is based upon the clinical observation that the normal flow of electricity in the human body is altered when its immune system is exposed to a substance to which it is sensitive or allergic. The ELAST Device(TM) is being designed to measure the body's electrical response, thereby providing an assessment of sensitivity.

This news release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product development and consumer demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.